Eric Wang, Ph.D.
Assistant Professor
Investigating mechanisms of drug resistance in hematological malignancies with the main goal to develop new therapeutic strategies and providing a blueprint for clinically relevant biomarkers.
Acute myeloid leukemia (AML) is an aggressive hematological malignancy that accounts for majority of acute leukemia cases in adults. Despite recent therapeutic advances, AML is still marked by a dismal prognosis. Our laboratory is interested in understanding mechanisms that govern therapy resistance in hematological malignancies by using CRISPR/Cas9 technology and genetically engineered mouse models.
-
Research HighlightOctober 23, 2023Examining the nongenetic drivers of acute leukemia drug resistance
Research from Eric Wang examines how nongenetic mechanisms of cancer development may represent therapeutic vulnerabilities that can be exploited to overcome drug resistance in acute myeloid leukemia and acute lymphoblastic leukemia.
-
Press ReleaseDecember 19, 2022An outstanding year of growth at The Jackson Laboratory
2022 has been a notable year for The Jackson Laboratory, with great achievements and many reasons to celebrate continued momentum for JAX’s mission.